Illumina, Inc. has announced the launch of the TruSight One Sequencing Panel, the industry’s broadest sequencing panel that targets 4,813 genes with known associated clinical phenotypes.
Clinical research laboratories can use this panel to expand existing menus, streamline workflows, or create an entire portfolio of sequencing options, with benefits including increased productivity, reduced handling errors, and decreased costs.
The power of the TruSight One Sequencing Panel is enhanced by Illumina’s user-friendly VariantStudio analysis and reporting software.
To coincide with the introduction of the TruSight One Sequencing Panel, VariantStudio will offer new features that expand annotation and filtering capabilities. These features include support for enabling family-based filtering (mother, father, child, and siblings), providing variant classifications, and generating ready-to-use reports.
In addition, the TruSight One Sequencing Panel can be used to create dozens of “virtual subpanels” to fit the needs of any clinical researcher seeking to understand the genetic basis of disease.
“Illumina is moving in the direction of one simple workflow which will drastically reduce the turnaround time from sample-to-report,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business.
Posard continued, “With the TruSight One Sequencing Panel and enhancements to VariantStudio, Illumina is providing clinical researchers with a simple, cost-effective solution that replaces small sequencing panels with a single robust platform.”
“Our genetics laboratory handles increasing numbers of requests to sequence a wide range of genes believed to be causing inherited disorders,” said Stephen Abbs, Director of Genetics Laboratories, Cambridge University Hospitals NHS Foundation Trust.
Abbs continued, “The broad coverage and high performance of the TruSight One Sequencing Panel allow us to perform these analyses using a streamlined laboratory workflow, as well as to offer a comprehensive, high-quality sequencing service.”